Two Sigma Advisers LP lifted its position in shares of Ventyx Biosciences, Inc. (NASDAQ:VTYX - Free Report) by 72.1% in the 4th quarter, according to its most recent Form 13F filing with the Securities & Exchange Commission. The institutional investor owned 800,800 shares of the company's stock after acquiring an additional 335,400 shares during the period. Two Sigma Advisers LP owned approximately 1.13% of Ventyx Biosciences worth $1,754,000 as of its most recent filing with the Securities & Exchange Commission.
Several other institutional investors and hedge funds also recently made changes to their positions in the company. Catalina Capital Group LLC bought a new stake in shares of Ventyx Biosciences in the 4th quarter worth $25,000. AXQ Capital LP bought a new stake in Ventyx Biosciences in the 4th quarter worth about $29,000. Palumbo Wealth Management LLC increased its holdings in Ventyx Biosciences by 97.1% in the 4th quarter. Palumbo Wealth Management LLC now owns 23,932 shares of the company's stock worth $52,000 after buying an additional 11,792 shares in the last quarter. MetLife Investment Management LLC raised its position in Ventyx Biosciences by 76.0% in the 4th quarter. MetLife Investment Management LLC now owns 26,731 shares of the company's stock worth $59,000 after buying an additional 11,543 shares during the last quarter. Finally, Wells Fargo & Company MN lifted its stake in Ventyx Biosciences by 23.3% during the 4th quarter. Wells Fargo & Company MN now owns 41,170 shares of the company's stock valued at $90,000 after acquiring an additional 7,768 shares during the period. Institutional investors own 97.88% of the company's stock.
Ventyx Biosciences Stock Performance
Shares of VTYX stock traded down $0.14 during trading hours on Friday, reaching $1.68. The company had a trading volume of 1,270,791 shares, compared to its average volume of 1,344,373. The business has a fifty day moving average price of $1.25 and a 200-day moving average price of $1.72. Ventyx Biosciences, Inc. has a one year low of $0.78 and a one year high of $5.66. The firm has a market cap of $119.19 million, a PE ratio of -0.71 and a beta of 0.73.
Ventyx Biosciences (NASDAQ:VTYX - Get Free Report) last released its quarterly earnings results on Thursday, May 8th. The company reported ($0.39) earnings per share for the quarter, beating the consensus estimate of ($0.48) by $0.09. Equities research analysts forecast that Ventyx Biosciences, Inc. will post -2.09 EPS for the current year.
Ventyx Biosciences Company Profile
(
Free Report)
Ventyx Biosciences, Inc, a clinical-stage biopharmaceutical company, develops small molecule product candidates to address a range of inflammatory diseases. The company's lead clinical product candidate is VTX958, a selective allosteric tyrosine kinase type 2 inhibitor for psoriasis, psoriatic arthritis, and Crohn's disease.
Further Reading
Before you consider Ventyx Biosciences, you'll want to hear this.
MarketBeat keeps track of Wall Street's top-rated and best performing research analysts and the stocks they recommend to their clients on a daily basis. MarketBeat has identified the five stocks that top analysts are quietly whispering to their clients to buy now before the broader market catches on... and Ventyx Biosciences wasn't on the list.
While Ventyx Biosciences currently has a Moderate Buy rating among analysts, top-rated analysts believe these five stocks are better buys.
View The Five Stocks Here
Which stocks are hedge funds and endowments buying in today's market? Enter your email address and we'll send you MarketBeat's list of thirteen stocks that institutional investors are buying now.
Get This Free Report
Like this article? Share it with a colleague.
Link copied to clipboard.
